Identification of three lncRNA-related prognostic signatures in gastric cancer by integrated multi-omics analysis
Abstract
Aims: The systematic identification of molecular features correlated with the clinical status of gastric cancer (GC) in patients is significant, although such investigation remains insufficient. Methods: GC subtyping based on RNA sequencing, copy number variation and DNA methylation data were derived from The Cancer Genome Atlas program. Prognostics lncRNA biomarkers for GC were identified by univariate Cox, LASSO and SVM-RFE analysis. Results: Three molecular subtypes with significant survival discrepancies, and their specific DEmRNAs and DElncRNAs were identified. Three reliable prognostic-associated lncRNA, including LINC00670, LINC00452 and LINC00160, were selected for GC. Conclusion: Our findings expanded the understanding on the regulatory network of lncRNAs in GC, providing potential targets for prognosis and treatment of GC patients.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
- 2. Chinese and global burdens of gastric cancer from 1990 to 2019. Cancer Med. 10(10), 3461–3473 (2021).
- 3. . Risk factors for gastric cancer: a systematic review. Asian Pac. J. Cancer Prev. 19(3), 591–603 (2018).
- 4. . Gastric cancer. Lancet 396(10251), 635–648 (2020).
- 5. Proposal and validation of a modified staging system to improve the prognosis predictive performance of the 8th AJCC/UICC pTNM staging system for gastric adenocarcinoma: a multicenter study with external validation. Cancer Commun. (Lond) 38(1), 67 (2018).
- 6. The prognostic value of preoperative fibrinogen-to-prealbumin ratio and a novel FFC score in patients with resectable gastric cancer. BMC Cancer 20(1), 382 (2020).
- 7. Signatures of copy number alterations in human cancer. Nature 606(7916), 984–991 (2022). • Describes the significance of copy number variations (CNVs) in cancers.
- 8. . Somatic copy number aberrations in metastatic patients: the promise of liquid biopsies. Semin. Cancer Biol. 60, 302–310 (2020).
- 9. Long noncoding RNA PiHL regulates p53 protein stability through GRWD1/RPL11/MDM2 axis in colorectal cancer. Theranostics 10(1), 265–280 (2020).
- 10. A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer. Cell Death Dis. 12(5), 485 (2021).
- 11. . A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 65(13), 5481–5484 (2005).
- 12. Identification of new susceptibility loci for gastric non-cardia adenocarcinoma: pooled results from two Chinese genome-wide association studies. Gut 66(4), 581–587 (2017).
- 13. Role of epigenetics in carcinogenesis: recent advancements in anticancer therapy. Semin. Cancer Biol. 83, 441–451 (2022). • Describes the significance of epigenetics in carcinogenesis.
- 14. LINC00261 Is an epigenetically regulated tumor suppressor essential for activation of the DNA damage response. Cancer Res. 79(12), 3050–3062 (2019).
- 15. . DNA methylation data-based molecular subtype classification and prediction in patients with gastric cancer. Cancer Cell Int. 20, 349 (2020). •• CNV-associated gastric cancer (GC) subtyping and their clinical significance for GC prognosis.
- 16. . Methylation-based signatures for gastroesophageal tumor classification. Cancers (Basel) 12(5), 1208 (2020). •• Methylation-based signatures for GC classification.
- 17. Identification and comprehensive characterization of lncRNAs with copy number variations and their driving transcriptional perturbed subpathways reveal functional significance for cancer. Brief. Bioinform. 21(6), 2153–2166 (2020).
- 18. Long non-coding RNAs in gastric cancer: new emerging biological functions and therapeutic implications. Theranostics 10(19), 8880–8902 (2020). • Functions and therapeutic implications of lncRNAs in GC.
- 19. . The role of long noncoding RNAs in hepatocellular carcinoma. Mol. Cancer 19(1), 77 (2020).
- 20. . Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. Gut 69(4), 748–763 (2020).
- 21. . RNA in cancer. Nat. Rev. Cancer 21(1), 22–36 (2021).
- 22. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 25(18), 1915–1927 (2011).
- 23. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci. Rep. 6, 25776 (2016).
- 24. Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy. Front. Immunol. 13, 951137 (2022).
- 25. . Unveiling DNA damage repair-based molecular subtypes, tumor microenvironment and pharmacogenomic landscape in gastric cancer. Front Genet 14, 1118889 (2023).
- 26. . MOVICS: an R package for multi-omics integration and visualization in cancer subtyping. Bioinformatics 36(22–23), 5539–5541 (2020).
- 27. . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28(11), 1747–1756 (2018).
- 28. . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12(4), R41 (2011).
- 29. . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15(12), 550 (2014).
- 30. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13(11), 2498–2504 (2003).
- 31. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb.) 2(3), 100141 (2021).
- 32. . circlize Implements and enhances circular visualization in R. Bioinformatics 30(19), 2811–2812 (2014).
- 33. ChAMP: 450k chip analysis methylation pipeline. Bioinformatics 30(3), 428–430 (2014).
- 34. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics 33(24), 3982–3984 (2017).
- 35. Integrated analysis of lncRNA–miRNA–mRNA ceRNA network in squamous cell carcinoma of tongue. BMC Cancer 19(1), 779 (2019).
- 36. Identification of CDK2-related immune forecast model and ceRNA in lung adenocarcinoma, a pan-cancer analysis. Front. Cell Dev. Biol. 9, 682002 (2021).
- 37. . Regularization paths for generalized linear models via coordinate descent. J. Stat Softw. 33(1), 1–22 (2010).
- 38. . SVM-RFE based feature selection and Taguchi parameters optimization for multiclass SVM classifier. Sci. World J. 2014, 795624 (2014).
- 39. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy. J. Mol. Med. (Berl.) 99(9), 1311–1321 (2021).
- 40. . The roles of immune cells in gastric cancer: anti-cancer or pro-cancer? Cancers (Basel) 14(16), 3922 (2022).
- 41. . Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. Ann. Oncol. 33(11), 1134–1148 (2022).
- 42. CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK/ERK axis. Drug Resist. Update 66, 100913 (2023).
- 43. . Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. Oncogene 35(12), 1475–1482 (2016).
- 44. . Comparison and applicability of molecular classifications for gastric cancer. Cancer Treat. Rev. 77, 29–34 (2019). • Describes the clinical applications of molecular classifications in GC.
- 45. . Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct. Target. Ther. 7(1), 265 (2022).
- 46. . DNA methylation and its basic function. Neuropsychopharmacology 38(1), 23–38 (2013).
- 47. LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res. 76(21), 6299–6310 (2016).
- 48. LncRNA MBNL1-AS1 represses gastric cancer progression via the TGF-β pathway by modulating miR-424-5p/Smad7 axis. Bioengineered 13(3), 6978–6995 (2022).
- 49. LncRNA NKX2-1-AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR-2 signaling pathway in gastric cancer. Mol. Oncol. 15(4), 1234–1255 (2021).
- 50. . H19 lncRNA: roles in tumorigenesis. Biomed. Pharmacother. 123, 109774 (2020).
- 51. . LncRNA TRHDE-AS1 and MiR-1275 as promising prognostic biomarkers and effects on tumor cell progression in gastric cancer. Tohoku J. Exp. Med. 261(1), 13–23 (2023).
- 52. LINC00160 mediated paclitaxel- and doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ. J. Cell Mol. Med. 24(15), 8589–8602 (2020).
- 53. . STAT3-regulated LncRNA LINC00160 mediates cell proliferation and cell metabolism of prostate cancer cells by repressing RCAN1 expression. Mol. Cell Biochem. 477(3), 865–875 (2022).
- 54. Epigenomics-based identification of oestrogen-regulated long noncoding RNAs in ER+ breast cancer. RNA Biol. 17(11), 1590–1602 (2020).
- 55. A myocardin-adjacent lncRNA balances SRF-dependent gene transcription in the heart. Genes Dev. 35(11–12), 835–840 (2021).